| This week's sponsor is CMIC Group. | | | Considering Japanese Market Entry?
As Japan's largest CRO with end-to-end solution, CMIC Group is your most experienced partner in Japan & the US. Our experts will help you determine the best strategy at any stage of drug development.
Click here to learn more! |
Today's Rundown Bispecifics player Abpro teams up with China’s NJCTTQ in biobucks deal worth up to $4B Novavax plummets after another phase 3 RSV study miss, this time in infants J&J bags option on AdoRx lung cancer drugs [Sponsored] Rise in Targeted Therapies Drives Need for Flexible, Small-Volume Manufacturing Horizon Pharma's inflammatory eye drug aces phase 3, poised for midyear BLA Denali expands antibody discovery deal with AbCellera Maze Therapeutics debuts with $191M to go after genetic modifiers Axial Biotherapeutics nets $25M for clinical gut-brain axis studies into autism and Parkinson’s StemoniX rakes in $14.4M for micro-organ drug testing chips built from stem cells Cohen drops testimony on Novartis deal: They wanted ‘access’ to Trump Featured Story | | | Thursday, February 28, 2019 Abpro is partnering with China-based NJCTTQ to develop new bispecific antibodies using its antibody discovery platform. Under the agreement, Abpro could collect up to $4 billion, which includes $60 million in “near-term R&D funding,” as well as milestone payments and royalties. |
|
|
| This week's sponsor is Sprout BioVentures. | | | Final Week for Golden Sprout Competition
Don’t miss out on 6 months of chemistry support at no cost. Strengthen your chemical starting points and work with a world-class research organization trusted by global biopharma. Click here to download the application. |
Top Stories Thursday, February 28, 2019 Once described as having the potential to become “the largest selling vaccine in the history of vaccines,” Novavax’s fusion protein nanoparticle shot against respiratory syncytial virus has missed another phase 3 trial, causing the company’s stock price to lose about two-thirds of its remaining value in premarket trading. Thursday, February 28, 2019 Johnson & Johnson is teaming up with AdoRx Therapeutics to develop lung cancer drugs. The deal gives J&J an exclusive option to research, develop and commercialize AdoRx antagonists. Monday, February 25, 2019 Biologics have experienced steady double-digit growth over the last 15 years and now comprise slightly more than a quarter of all New Molecular Entity (NME) FDA approvals. Thursday, February 28, 2019 Horizon Pharma’s inflammatory eye drug teprotumumab met its primary endpoint in a phase 3 study, with topline data showing the drug beat out placebo in reducing proptosis, or bulging of the eye. The candidate also met its secondary endpoints, and Horizon plans to submit a BLA in mid-2019. Thursday, February 28, 2019 Denali Therapeutics has expanded its antibody discovery deal with AbCellera. The agreement tasks AbCellera with generating panels of antibodies for up to eight targets picked by Denali. Thursday, February 28, 2019 Maze Therapeutics aims to make sense of the proliferation of human genetic data that has emerged in recent years and understand how some genes provide protection against disease so that they can be targeted with drugs. Wednesday, February 27, 2019 Axial Biotherapeutics has raised $25 million to fund its programs aimed at the gut microbiome, for the treatment of Parkinson’s disease and autism spectrum disorder. Thursday, February 28, 2019 Microtissue developer StemoniX has secured $14.4 million in funding to commercialize its organ-on-a-chip platforms for drug development. Wednesday, February 27, 2019 In congressional testimony, Michael Cohen sketched out a relationship that contradicts Novartis' original version in some important ways—namely, regarding how often the company interacted with Cohen and what, exactly, Novartis wanted him to do. Resources Sponsored by: ON24 Which HCP Touchpoints and channels are yielding the best results in today’s digital world? Sponsored by: Blue Matter White paper outlining the key types of cell-based immunotherapies in oncology, as well as the development and commercial outlook for each. Sponsored by: AlphaSense It’s never been more challenging to stay on top of trends and innovation shaping the future of healthcare. Discover how AI can help competitive intelligence teams achieve more proactive strategies. Sponsored by: Patheon, part of Thermo Fisher Scientific When a biologics company prepares to launch a new product, it must forecast the manufacturing capacity it will need, factoring in its estimate of the size of future sales, the timing of the launch, the dosage of the product, its strategy for building its market and a host of other variables. Sponsored by: Oracle Health Sciences 92% of survey respondents make changes to their RTSM/IRT systems due to study changes. See what else puts a strain on their clinical trials. Download the Research Whitepaper. Sponsored by: Patheon, part of Thermo Fisher Scientific Download this whitepaper to learn more. Sponsored by: The Kinetix Group Explore how the pharma industry can adapt its approach to the changing healthcare marketplace in the era of the Quadruple Aim Sponsored by: Cofactor Genomics Learn how Health Expression Models provide increased sensitivity, specificity, and accuracy for characterizing immune response in solid tumor specimens. Sponsored by: BioAnalytix, Inc. This whitepaper reviews fundamental aspects of HCPs that pertain to biologic drug development and presents current and emerging approaches to HCP analysis. Sponsored by: Veradigm Clinical trials take too long and cost too much—here's what needs to change. Sponsored by: Outer Edge Technology With FDA approval imminent, start-up Life Sciences company partners with an industry focused MSP to design and manage its regulated cloud-based infrastructure to speed time to market. Presented by: Veeva Share your thoughts on the life sciences industry's progress in improving study execution. Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. BIO Asia International Conference March 5-6, 2019 | Grand Hyatt Tokyo | Tokyo, Japan BioBasics: Biotech For The Non-Scientist March 28-29, 2019 | Boston, MA Drug Development Immersion April 3-4, 2019 | Philadelphia, PA PEGS: The Essential Protein Engineering Summit April 8 – 12, 2019 | Boston, MA Middle East Life Sciences Compliance Training April 29, 2019 – May 2, 2019 | Dubai U.A.E. 2019 BIO International Convention June 3-6, 2019 | Philadelphia, PA Drug Development Boot Camp® 2019 November 20-21, 2019 | Boston, MA | Register and start preparing Today! | 